EXCLUSIVE

Home visits are the key to patient retention, says ResearchNurses.co

By Natalie Morrison

- Last updated on GMT

Related tags: Patient, Health care

Including home visits in clinical trial designs could be the key to patient retention, according to ResearchNurses.co.

The UK-based research nurse provider says that by providing a regular, trusted point of contact to help administer the drugs and deal with the finer details, participants are much more likely to stay in the trial.

Other benefits, says the firm, include improved patient compliance – because a trained healthcare professional is there to help administer the drug and ensure trial data is completed accurately – as well as initial clinical assessments performed before samples hit the lab.

Speaking to Outsourcing-Pharma, Sue Mackay, research nursing team manager, said: “If it does mean that we’re getting perfect data that is absolutely clean, we’re getting patient compliance and retention within the studies then in the long run that is going to benefit people.”

False economy?

Mackay added that, although the initial outlay for such individualised patient care is higher than having the patient come to the research centre, in the long-run it saves money.

To me it’s a bit of a double edge sword​,” she said. “It’s one thing to recruit patients but it’s another to retain them. It would cost more to recruit all over again.

She added: “I think a lot of studies are beginning to look quite seriously at home care studies, especially for long-term diseases.”

Part II of the podcast coming up tomorrow. Mackay discusses the regulatory benefits, and changing views of Big Pharma towards home visits.

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Products

View more

Webinars